Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2036-2048

  Shi, Wei ^a,b   Alajez, Nehad M ^a,b   Bastianutto, Carlo ^a,b   Hui, Angela B Y ^a,b   Mocanu, Joseph D ^a,b   Ito, Emma ^a,b   Busson, Pierre ^c   Lo, Kwok Wai ^d   Ng, Raymond ^e   Waldron, John ^b,f   O'Sullivan, Brian ^b,f   Liu, Fei Fei ^a,b,f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e Rouge Valley Health System   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Human nasopharyngeal carcinoma; Ionizing radiation; MicroRNAs; Plk1

Indexed keywords

CASPASE; DOUBLE STRANDED DNA; MESSENGER RNA; MICRORNA; MICRORNA 100; POLO LIKE KINASE 1; PROTEIN CDC25C; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT PROTEIN; SIPLK1 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; MIRN100 MICRORNA, HUMAN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA FLANKING REGION; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; MITOSIS INHIBITION; MITOSIS SPINDLE; MOUSE; NASOPHARYNX CANCER; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; TUMOR BIOPSY; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; HISTONES; HUMANS; MICE; MICE, INBRED BALB C; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 77949904204     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24880     Document Type: Article

References (50)

1. Lee AW, Yau TK, Wong DH, Chan EW, Yeung RM, Ng WT, Tong M, Soong IS, Sze WM. Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys 2005;63:1331-1338
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4: 757-768
3. Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, Pinto HA, Terris DJ, Fee WE, Goffinet DR. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003;56: 1046-1054
4. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-641
5. Mortlock AA, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson RW, Green S. Progress in the development of selective inhibitors of aurora kinases. Curr Top Med Chem 2005;5:807-821 (Pubitemid 41183689)
6. Strebhardt K, Ullrich A. Targeting pololike kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330
7. Glover DM, Hagan IM, Tavares AA. Pololike kinases: a team that plays throughout mitosis. Genes Dev 1998;12:3777-3787
8. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-348
9. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000;2:672-676
10. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005;24:2844-2859
11. van Vugt MA, Medema RH. Checkpoint adaptation and recovery: back with Polo after the break. Cell Cycle 2004;3:1383-1386
12. Kraft C, Herzog F, Gieffers C, Mechtler K, Hagting A, Pines J, Peters JM. Mitotic regulation of the human anaphase-promoting complex by phosphorylation. EMBO J 2003;22:6598-6609
13. Casenghi M, Meraldi P, Weinhart U, Duncan PI, Korner R, Nigg EA. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev Cell 2003;5:113-125
14. Llamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, Gonzalez C, Karess RE, Glover DM, Sunkel CE. Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 1991; 5:2153-2165
15. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 2002;99: 8672-8676
16. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14:543-549
17. Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000;196:753-759
18. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001;164:41-49
19. Ahmad N. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J 2004;18:5-7.
20. Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S, Buckendahl AC, Dietel M, Denkert C. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 2006;97: 271-276
21. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59: 2794-2797
22. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29:354-358
23. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701-1713
24. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005;19:611-613
25. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009;69: 1916-1923
26. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75: 843-854
27. Esquela-Kerscher A, Slack FJ. Oncomirs\ microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
28. Krek A, Grun D, Poy MN, Wolf R Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005;37: 495-500.
29. Shi W, Bastianutto C, Li A, Perez-Ordonez B, Ng R, Chow KY, Zhang W, Jurisica I, Lo KW, Bayley A, Kim J, O'Sullivan B, et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 2006;119:2467-2475
30. Li JH, Shi W, Chia M, Sanchez-Sweatman O, Siatskas C, Huang D, Busson P, Klamut H, Yeh WC, Richardson C, O'Sullivan B, Gullane P, et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 2003;8:964-973
31. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, Bastianutto C, Liu FF. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 2005;11:8131-8144
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(\Delta Delta C(T)) method. Methods 2001;25: 402-408
33. MacPhail SH, Banath JP, Yu Y, Chu E, Olive PL. Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res 2003; 159:759-767
34. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-4350
35. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008;105: 5874-5878
36. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Jurisica I, Penn LZ, Liu FF. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009;89: 597-606.
37. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Pololike kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001;410:215-220
38. Wasch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 2005; 24:1-10.
39. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-2704
40. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-2108
41. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100: 5789-5794
42. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26:5793-5807
43. Tannock IF, Hill RP, Bristow RG, Harrington L, eds. The basic science of oncology. New York: McGraw-Hill,2005.
44. Syljuasen RG, Jensen S, Bartek J, Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 2006;66:10253-10257
45. Jang YJ, Ji JH, Choi YC, Ryu CJ, Ko SY. Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A. J Biol Chem 2007;282:2473-2482
46. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68: 383-424.
47. Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O'Sullivan B, Cummings BJ, Warde P, Liu FF. Molecular athology parameters in human nasopharyngeal carcinoma. Cancer 2002;94: 1997-2006.
48. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, Liu FF. Prognostic significance of the Epstein-Barr virus, p53. Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006;12:5726-32.
49. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68: 425-433
50. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008;14: 2588-2592